| Literature DB >> 18047260 |
Abstract
Evidence of epidemiological associations of vitamins and disease states have been found for nine vitamins. In observational studies, people with a high intake of antioxidant vitamins by regular diet or as food supplements generally have a lower risk of major chronic disease, such as myocardial infarction or stroke, than people who are low consumers of antioxidant vitamins. Prospectively, folate appears to reduce the incidence of neural tube defects. Vitamin D is associated with a decreased occurrence of fractures when taken with calcium. Zinc, betacarotene, and vitamin E appear to slow the progression of macular degeneration, but do not reduce the incidence. Vitamin E and lycopene may decrease the risk of prostate cancer. In other randomized controlled trials, the apparent beneficial results of a high intake of antioxidant vitamins seen in observational studies have not been confirmed. There is increasing concern from these trials that pharmacological supplementation of vitamins may be associated with a higher mortality risk.Entities:
Mesh:
Substances:
Year: 2006 PMID: 18047260 PMCID: PMC2682456 DOI: 10.2147/ciia.2006.1.1.81
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Examples of epidemiological associations with diet, vitamins, or supplements with specific diseases
| Study | Population | Condition | Association | Results | 95% CI |
|---|---|---|---|---|---|
| 167 women aged 15–44 years vs 328 women without a stroke | First ischemic stroke | Plasma homocysteine level ≥ 7.3 μmol/L | Odds ratio 1.6 | 1.1–2.5 | |
| Cancer Prevention Study 2000 – | 26 593 male smokers,aged 50–69 years | Cerebral infarction | Dietary intake of p-carotene | Relative risk 0.77 | 0.61–0.99 |
| Cancer Prevention Study 2002 – | 26 593 male smokers, aged 50–69 years | Cerebral infraction | Lycopene, lutein,zeaxanthin, Vitamin C, flavonols, flavones, vitamin E | No association | |
| 750 patients vs 800 controls | Coronary artery, disease | Homocysteine concentrations >80th percentile of control subjects | Increased risk | ||
| 750 patients vs 800 controls | Coronary artery disease | Red cell folate < 10th percentile of controls | Increased risk | ||
| 750 patients vs 800 controls | Coronary artery disease | Vitamin B6 < 20th percentil of controls | Increased risk | ||
| 1412 patients | Coronary artery disease | Plasma total homocysteine levels | Higher 3-year mortality | 15.7% vs 9.6% | |
| 83 639 male US physicians with no history of cardiovascular disease (CVD) or cancer | Cardiovascular disease or cardiovascular mortality | Self-reported use of vitamins E, C, or multivitamins | No association | ||
| 71 910 female participants in the Nurses' Health Study and 37 725 male participants in the Health Professionals' Follow-Up Study, free of chronic disease | Incidence of cardiovascular disease, cancer, or death | Total fruit and vegetable intake by dietary questionnaire | Relative risk for major chronic disease of 0.95 for highest quintile vs lowest, Relative risk for greater than 5 servings daily 0.88 for cardiovascular disease and 1.00 for cancer | 0.89–1.01 for major chronic disease; 0.81–0.95 for cardiovascular disease; 0.95–1.05 for cancer | |
| 15 317 men and women > 20 years of age | Hypertension | Lower levels of vitamin A and vitamin E | Higher risk of hypertension | 43% vs 18% | |
| 15 317 men and women > 20 years of age | Hypertension | Higher levels of alphacarotene and betacarotene | Lower risk of hypertension | 16% vs 11% | |
| 15 317 men and women >20 years of age | Hypertension | Higher levels of vitamin C | Lower diastolic pressure | ||
| Finland (n = 1248), Italy (n = 1386), and the Netherlands (n = 691) middle-aged men | Pulmonary | Higher intake of fruits, vegetables | Higher forced vital capacity | 53 mL–118 mL | |
| Finland (n = 1248), Italy (n = 1386), and the Netherlands (n = 691) middle-aged men | Pulmonary | Higher intake of vitamin C, betacarotene | No association | ||
| Finland (n = 1248),Italy (n = 1386), and the Netherlands (n = 691) middle-aged men | Pulmonary | Higher intake of vitamin E | No association | ||
| 9345 Japanese-American men | Bladder cancer | Alphacarotene, betacarotene, lutein plus zeaxanthin, betacryptoxanthin and total carotenoids | No association after adjusting for smoking | ||
| 980 elderly subjects free of dementia at baseline, followed for mean 4 years | Alzheimer disease | Carotenes and vitamin C, or vitamin E in supplemental or dietary (nonsupplemental) form or in both forms | No association |
Examples of controlled trials of vitamins or supplements on specific diseases
| Study | Population | Condition | Intervention | Results | Effect |
|---|---|---|---|---|---|
| 20 536 subjects followed 5 years | Coronary heart disease, vascular occlusive disease, diabetes mellitus, hyper tension | Vitamin E 600 mg/d, plus vitamin C 250 mg/d, plus betacarotene 20 mg/d or placebo | All-cause, vascular, or nonvascular mortality, or secondary measures including major coronary events, stroke, revascularization, and cancer | No difference | |
| The SU.VI.MAX Study 2004 – | 13 017 persons, age 45–60, followed 7.5 years | Cancer, cardiovascular disease or cardiovascular mortality | 120 mg ascorbic acid, 30 mg of vitamin E, 6 mg of betacarotene, 100 μg of selenium, 20 mg of zinc vs placebo | Total cancer incidence 4.1% vs 4.5%; ischemic cardiovascular disease incidence 2.1% vs 2.1%, all-cause mortality 1.2% vs 1.5% | No difference; may have small protective effect in men |
| 3994 persons, > 55 years with CVD or cardiovascular disease; diabetes mellitus followed 7 years | Cardiovascular events and cancer | Vitamin E 400 IU/d vs placebo | Cancer incidence 11.6% vs 12.3%; cancer deaths 3.3% vs 3.7%; major cardiovascular events 21.5% vs 20.6% | No difference. Higher risk of congestive heart failure (CHF) and hospitalization for CHF | |
| 15 000 men aged 40–80, followed 5 years | Cardiovascular disease | Daily combination of vitamin E (600 mg) vitamin C (250 mg), and betacarotene (20 mg) | Incidence | No significant reduction | |
| Meta-analysis 2005 – | 135 967 participants in 19 clinical trials | All-cause mortality | Vitamin E≥400 IU/d | 39 deaths per 10 000 persons (3–74 per 10 000 persons; p = 0.035) | Higher mortality |
| 30 patients, 45–70 years old, with type 2 diabetes, followed 4 weeks | Hypertension | 500 mg of ascorbic acid daily | Mean systolic 9.9 mmHg, mean diastolic 6.0 mmHg | Reduced systolic blood pressure | |
| 439 subjects followed 5 years | Hypertension | 500 mg of vitamin C daily | Blood pressure | No reduction | |
| 148 women, mean age 74 years | Hypertension | 1200 mg calcium plus 800 IU vitamin D3 or 1200 mg calcium/day | Decrease in systolic blood pressure of 9.3% | Improved | |
| Six trials | Asthma | Vitamin C supplementation | Asthma outcome | No difference | |
| 109 394 subjects | Lung cancer | Betacarotene, alone or combination with alphatocopherol or retinol, or alphatocopherol alone | Cancer incidence | No reduction | |
| The Betacarotene and Retional Efficacy Trial 1996 – | 18 314 subjects, 45–74 years, at high risk, followed 4 years | Lung cancer | Betacarotene and retinyl palmitate compared with placebo | 28% (4%–57%) higher cancer incidence and 17% (3%–33%) higher total mortality in the supplemented group | Worse outcome |
| 25 390 persons followed 6 years | Prostate cancer | Alphatocopherol | Relative risk 0.88 (0.76–1.03) | No difference | |
| 25 390 persons followed 6 years | Prostate cancer | Betacarotene | Relative risk 1.06 (0.91–1.23) | No difference | |
| 864 subjects | Incidence of colon polyps | Placebo, betacarotene (25 mg daily), vitamin C (1 g daily) and vitamin E (400 mg daily), or betacarotene plus vitamins C and E | Relative risk 1.01 (0.85–1.20) for betacarotene and 1.08 (0.91 to 1.29) for vitamin C and E | No difference | |
| 50 subjects, followed 1 year | Alzheimer dementia | Thiamine supplementation | Cognitive status | No benefit | |
| Alzheimer's Disease Cooperative Study 1997 – | 341 subjects followed 2 years | Alzheimer dementia | Vitamin E 1000 mg twice a day, selegiline 5 mg twice a day, both or placebo | Time to either death, institutionalization, decline in activities of daily living, or progression to severe dementia | Reduced in vitamin E group (670 days) and selegiline group (655 days) compared with placebo group (440 days), higher mortality 1.08 (1.01–1.14) |
| 15 subjects | Schizophrenia | Vitamin B6 400 mg vs placebo | Mental status | No difference | |
| 247 subjects | Depression | Folic acid | Reduction in depression scores | 2.65 points, CI 0.38–4.93 | |
| 22 071 male US physicians aged 40–84 years, followed 1 year | Cataract | Betacarotene 50 mg on alternate days vs placebo | Incidence | No benefit | |
| 4119 subjects in 7 trials | Age-related macular degeneration, progression to advanced disease | Antioxidant and zinc supplementation | Risk ratio 0.72 (0.52–0.98) | Less risk | |
| 4119 subjects in 7 trials | Age-related macular degeneration | Vitamin E, betacarotene or both | Prevention | No benefit | |
| 725 institutionalized elderly subjects > 65 years, followed 2 years | Antibody titers, respiratory infections, urinary tract infections, survival rate | Trace elements (zinc and selenium sulfide) or vitamins (betacarotene, ascorbic acid, and vitamin E) or a placebo | Antibody titers after influenza vaccine were higher in group that received trace elements alone or associated with vitamins, but the vitamin group had significantly lower antibody titers | Higher titers with minerals but low with vitamins | |
| 96 subjects | Infection-related illness, days taking antibiotics, nutritional deficiencies | Vitamin A 400 units, betacarotene 16 mg; thiamine 2.2 mg; riboflavin 1.5 mg; niacin 16 mg; vitamin B6 3.0 mg; folate 400 μg; vitamin C 80 mg; vitamin D 4 μg; vitamin E 44 mg; iron 16 mg; zinc 14 mg; copper 1.4 mg; selenium 20 μg; iodine 0.2 mg; calcium 200 mg; and magnesium 100 mg vs placebo (calcium, 200 mg, and magnesium, 100 mg) | 23 (23–28) vs 48 fewer infection-related illness days; 18 (12–16) vs 32 fewer days taking antibiotics | Improved | |
| 8 trials in older adults | Days with infection, at least one infection, incident infections | Any combination of vitamin or mineral supplements | 14(10–18) fewer days with infection; at least one infection 1.10 (0.81–1.50); incident infections 0.89 (0.78–1.03) | Fewer days with infection, no difference in incident infections | |
| Frail elderly subjects | Hip fracture and vertebral fracture incidence | Vitamin D3 supplementation along with calcium | Risk ratio 0.74 (0.60–0.91) | Less risk | |
| Frail elderly subjects | Hip fracture and vertebral fracture incidence | Vitamin D3 supplementation alone without calcium | Risk ratio 1.20 (0.83–1.75) | No difference | |
| In healthy younger, ambulatory subjects | Hip fracture | Vitamin D3 supplementation along with calcium | Risk ratio 0.36 (0.01–8.78) | No difference | |
| In healthy younger, ambulatory subjects | Nonvertebral fracture | Vitamin D3 supplementation alone with calcium | Risk ratio 0.46 (0.23–0.90) | Less risk |